mTOR Cross-Talk in Cancer and Potential for Combination Therapy

Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma

(2017) James J. Hsieh et al.   EUROPEAN UROLOGY

OA06.06 Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC)

(2017) Sara Pilotto et al.   Journal of Thoracic Oncology

Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation

(2017) John K. Simmons et al.   MOLECULAR CANCER THERAPEUTICS

Marked for death: targeting epigenetic changes in cancer

(2017) Sophia Xiao Pfister et al.   NATURE REVIEWS DRUG DISCOVERY

Twenty-five years of mTOR: Uncovering the link from nutrients to growth

(2017) David M. Sabatini   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study

(2017) Fleur Weeber et al.   Oncotarget

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy

(2017) Vincent Chung et al.   JAMA Oncology

Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities

(2017) Claudio Pulito et al.   Cell Discovery

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer

(2017) Michele Milella et al.   Scientific Reports

The PI3K/AKT Pathway as a Target for Cancer Treatment

(2016) Ingrid A. Mayer et al.   Annual Review of Medicine

Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers

(2016) M. Morrison Joly et al.   CANCER RESEARCH

Tuberous sclerosis complex: From molecular biology to novel therapeutic approaches

(2016) Katarzyna Switon et al.   IUBMB LIFE

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3

(2016) Fabrice André et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

(2016) James C Yao et al.   LANCET

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor

(2016) Vanessa S. Rodrik-Outmezguine et al.   NATURE

Epigenomic regulation of oncogenesis by chromatin remodeling

(2016) R Kumar et al.   ONCOGENE

mTORC1 and mTORC2 in cancer and the tumor microenvironment

(2016) L C Kim et al.   ONCOGENE

mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle

(2016) I. Ben-Sahra et al.   SCIENCE

The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study

(2016) Peter Tan et al.   Oncotarget

Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents

(2016) Yu Liu et al.   Oncotarget

Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus

(2016) Sun Min Lim et al.   Oncotarget

The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway

(2016) Lioubov G. Korotchkina et al.   Aging-US

Therapeutic potential of mTOR inhibitors for targeting cancer stem cells

(2015) Maria Giovanna Francipane et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy

(2015) A. M. Eiden et al.   CLINICAL CANCER RESEARCH

A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma

(2015) Ravindran Kanesvaran et al.   Clinical Genitourinary Cancer

Drugging PI3K in cancer: refining targets and therapeutic strategies

(2015) Timothy A Yap et al.   CURRENT OPINION IN PHARMACOLOGY

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

(2015) Robert J Motzer et al.   LANCET ONCOLOGY

Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus

(2015) H. Huynh et al.   MOLECULAR CANCER THERAPEUTICS

Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis

(2015) Teguh Haryo Sasongko et al.   Orphanet Journal of Rare Diseases

Intersection of mTOR and STAT signaling in immunity

(2015) Diana Saleiro et al.   TRENDS IN IMMUNOLOGY

Current treatment strategies for inhibiting mTOR in cancer

(2015) Francesca Chiarini et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors

(2015) H. Cheng et al.   Cancer Discovery

PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex

(2015) P. Liu et al.   Cancer Discovery

PTEN: Multiple Functions in Human Malignant Tumors

(2015) Michele Milella et al.   Frontiers in Oncology

mLST8 Promotes mTOR-Mediated Tumor Progression

(2015) Kyoko Kakumoto et al.   PLoS One

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors

(2014) A. W. Tolcher et al.   ANNALS OF ONCOLOGY

Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations

(2014) M Moschetta et al.   BRITISH JOURNAL OF PHARMACOLOGY

mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels

(2014) Kaveh M Goudarzi et al.   CANCER BIOLOGY & THERAPY

Rapamycin: One Drug, Many Effects

(2014) Jing Li et al.   Cell Metabolism

Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy

(2014) M. H. Voss et al.   CLINICAL CANCER RESEARCH

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

(2014) Fabrice André et al.   LANCET ONCOLOGY

TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms

(2014) John K. Simmons et al.   Molecular Oncology

Autophagy, p53, and Pancreatic Cancer

(2014) Christine A. Iacobuzio-Donahue et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer

(2014) Nikhil Wagle et al.   NEW ENGLAND JOURNAL OF MEDICINE

mTORC1 signaling controls multiple steps in ribosome biogenesis

(2014) Valentina Iadevaia et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

(2014) B. C. Grabiner et al.   Cancer Discovery

NF- B, an Active Player in Human Cancers

(2014) Y. Xia et al.   Cancer Immunology Research

Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer

(2013) Parvin F. Peddi et al.   CANCER TREATMENT REVIEWS

Ablation of the mTORC2 component rictor in brain or Purkinje cells affects size and neuron morphology

(2013) Venus Thomanetz et al.   JOURNAL OF CELL BIOLOGY

Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy

(2013) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

(2013) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma

(2013) Thomas E. Hutson et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial

(2013) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

p53 status determines the role of autophagy in pancreatic tumour development

(2013) Mathias T. Rosenfeldt et al.   NATURE

Signals from the lysosome: a control centre for cellular clearance and energy metabolism

(2013) Carmine Settembre et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features

(2013) ELENI ANDRIANA TRIGKA et al.   ONCOLOGY REPORTS

mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms

(2013) Costanza Bogani et al.   PLoS One

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy

(2013) M. Weiler et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1

(2013) I. Ben-Sahra et al.   SCIENCE

mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin

(2013) S. A. Kang et al.   SCIENCE

A Tumor Suppressor Complex with GAP Activity for the Rag GTPases That Signal Amino Acid Sufficiency to mTORC1

(2013) L. Bar-Peled et al.   SCIENCE

Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial

(2013) Mary E. Peterson   SUPPORTIVE CARE IN CANCER

Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

(2013) J. M. Balko et al.   Cancer Discovery

Role of PRAS40 in Akt and mTOR signaling in health and disease

(2012) Claudia Wiza et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model

(2012) Cun Wang et al.   BMC CANCER

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

(2012) F. Meric-Bernstam et al.   CLINICAL CANCER RESEARCH

mTOR Signaling Pathway and mTOR Inhibitors in Cancer Therapy

(2012) Alejandro Gomez-Pinillos et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas

(2012) Penelope Korkolopoulou et al.   HISTOPATHOLOGY

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

(2012) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms

(2012) Ludovica Ciuffreda et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

TBC1D7 Is a Third Subunit of the TSC1-TSC2 Complex Upstream of mTORC1

(2012) Christian C. Dibble et al.   MOLECULAR CELL

mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake

(2012) Ömer H. Yilmaz et al.   NATURE

PRR5L degradation promotes mTORC2-mediated PKC-δ phosphorylation and cell migration downstream of Gα12

(2012) Xiaoqing Gan et al.   NATURE CELL BIOLOGY

Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity

(2012) D. W. Lamming et al.   SCIENCE

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

(2012) G. Iyer et al.   SCIENCE

PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies

(2012) Lise Willems et al.   Current Oncology Reports

Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma

(2011) Ana M. Molina et al.   CANCER

mTORC1 and mTORC2 Regulate EMT, Motility, and Metastasis of Colorectal Cancer via RhoA and Rac1 Signaling Pathways

(2011) P. Gulhati et al.   CANCER RESEARCH

mTOR complex 2 signaling and functions

(2011) Won Jun Oh et al.   CELL CYCLE

A Central Role for mTOR Kinase in Homeostatic Proliferation Induced CD8+ T Cell Memory and Tumor Immunity

(2011) Qingsheng Li et al.   IMMUNITY

Convergence of the Mammalian Target of Rapamycin Complex 1- and Glycogen Synthase Kinase 3- -Signaling Pathways Regulates the Innate Inflammatory Response

(2011) H. Wang et al.   JOURNAL OF IMMUNOLOGY

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

Regulation of mTORC1 Complex Assembly and Signaling by GRp58/ERp57

(2011) I. Ramirez-Rangel et al.   MOLECULAR AND CELLULAR BIOLOGY

Rac1 Regulates the Activity of mTORC1 and mTORC2 and Controls Cellular Size

(2011) Abdelhafid Saci et al.   MOLECULAR CELL

mTOR Drives Its Own Activation via SCFβTrCP-Dependent Degradation of the mTOR Inhibitor DEPTOR

(2011) Daming Gao et al.   MOLECULAR CELL

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling

(2011) Y. Yu et al.   SCIENCE

The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling

(2011) P. P. Hsu et al.   SCIENCE

Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids

(2010) Yasemin Sancak et al.   CELL

The mTOR Pathway: A New Target in Cancer Therapy

(2010) L. Ciuffreda et al.   CURRENT CANCER DRUG TARGETS

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer

(2010) Sébastien Albert et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The mTOR Kinase Determines Effector versus Memory CD8 + T Cell Fate by Regulating the Expression of Transcription Factors T-bet and Eomesodermin

(2010) Rajesh R. Rao et al.   IMMUNITY

Rapamycin Inhibits Cytoskeleton Reorganization and Cell Motility by Suppressing RhoA Expression and Activity

(2010) Lei Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Tti1 and Tel2 Are Critical Factors in Mammalian Target of Rapamycin Complex Assembly

(2010) Takeshi Kaizuka et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Versatile Role of Mammalian Target of Rapamycin in Human Dendritic Cell Function and Differentiation

(2010) M. Haidinger et al.   JOURNAL OF IMMUNOLOGY

Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1

(2010) Katrin Düvel et al.   MOLECULAR CELL

mTOR: from growth signal integration to cancer, diabetes and ageing

(2010) Roberto Zoncu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

(2010) S. A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer

(2010) T Sato et al.   ONCOGENE

Paradoxical suppression of cellular senescence by p53

(2010) Z. N. Demidenko et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs

(2010) R. J. O. Dowling et al.   SCIENCE

Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice

(2009) M. G. Kharas et al.   BLOOD

mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice

(2009) David A. Guertin et al.   CANCER CELL

Signaling Events Downstream of Mammalian Target of Rapamycin Complex 2 Are Attenuated in Cells and Tumors Deficient for the Tuberous Sclerosis Complex Tumor Suppressors

(2009) J. Huang et al.   CANCER RESEARCH

DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival

(2009) Timothy R. Peterson et al.   CELL

mTOR Mediates Wnt-Induced Epidermal Stem Cell Exhaustion and Aging

(2009) Rogerio M. Castilho et al.   Cell Stem Cell

ULK1·ATG13·FIP200 Complex Mediates mTOR Signaling and Is Essential for Autophagy

(2009) Ian G. Ganley et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Nutrient-dependent mTORC1 Association with the ULK1–Atg13–FIP200 Complex Required for Autophagy

(2009) Nao Hosokawa et al.   MOLECULAR BIOLOGY OF THE CELL

ULK-Atg13-FIP200 Complexes Mediate mTOR Signaling to the Autophagy Machinery

(2009) Chang Hwa Jung et al.   MOLECULAR BIOLOGY OF THE CELL

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

Molecular mechanisms of mTOR-mediated translational control

(2009) Xiaoju Max Ma et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Hsp70 associates with Rictor and is required for mTORC2 formation and activity

(2008) Jheralyn Martin et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The TSC1–TSC2 complex: a molecular switchboard controlling cell growth

(2008) Jingxiang Huang et al.   BIOCHEMICAL JOURNAL

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)

(2008) Juan M. García-Martínez et al.   BIOCHEMICAL JOURNAL

Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells

(2008) M. Ohtani et al.   BLOOD

Oncogenic MAPK Signaling Stimulates mTORC1 Activity by Promoting RSK-Mediated Raptor Phosphorylation

(2008) Audrey Carrière et al.   CURRENT BIOLOGY

Hypoxia regulates TSC1/2 mTOR signaling and tumor suppression through REDD1-mediated 14 3 3 shuttling

(2008) M. P. DeYoung et al.   GENES & DEVELOPMENT

TSC–mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species

(2008) Chong Chen et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML

(2008) K Kojima et al.   LEUKEMIA

AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint

(2008) Dana M. Gwinn et al.   MOLECULAR CELL

The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1

(2008) Y. Sancak et al.   SCIENCE